C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026C-FORWARD ...

Operator: Ladies and gentlemen, thank you for joining, and welcome to the Innate Pharma First Quarter 2026 Business Update and Financial Results.

Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...

Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Ruzasvir has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. Ruzasvir has been administered to over 2,800 HCV-infected patients ...

Versus Q4 2025’s data-centric call, Q1 2026 added a more execution-and-capital framing, with Chris Ogden emphasizing “projected cash runway to at least the second half of 2028,” supporting a sustained ...

While smartphones have taken on the roles of many standalone devices, people are finding a newfound appreciation for doing ...

Overview: Despite the fast-growing popularity of online learning platforms, core electronics engineering books are still a ...

Recently, ACROBiosystems successfully held its Innovation Day at Superlab Suisse Zürich Schlieren in Zurich, Switzerland, a ...

In Newport County, where the need for behavioral health services continues to grow, those outcomes are both hard-won and ...

The end of an era in tailhook aviation.

Looking for a way to connect has spiraled into violence at some teen gatherings ...